Hepatic Steatosis in Primary Aldosteronism, Cushing’s Syndrome, and Mild Autonomous cortisol secretion: Metabolic and Hormonal Associations

CONTEXT: Metabolic dysfunction-associated steatotic liver disease (MASLD) is closely linked to obesity, diabetes mellitus (DM), and dyslipidemia. Patients with primary aldosteronism (PA), Cushing's syndrome (CS) and mild autonomous cortisol secretion (MACS) exhibit metabolic abnormalities, but the relative contributions of hormonal and metabolic factors to hepatic steatosis remain unclear. OBJECTIVE: To evaluate MASLD prevalence and determinants in PA, CS, and MACS. DESIGN: Single-center retrospective cross-sectional study. METHODS: 243 treatment-naive patients underwent unenhanced abdominal computed tomography: 102 isolated PA, 60 CS, 47 MACS, and 34 PA with cortisol co-secretion. Hepatic steatosis was assessed using liver-to-spleen (L/S) attenuation ratio. Hepatic steatosis index (HSI), and triglyceride-glucose (TyG) index were calculated. RESULTS: MASLD prevalence was 28.4% in isolated PA, 26.6% in CS, 31.9% in MACS and 26.4% in PA with cortisol co-secretion. Liver attenuation and L/S ratio were similar across groups but correlated with visceral adiposity, glucose, HbA1c, triglycerides, HSI, and TyG index (all r>0.5, p<0.05). DM was independently associated with lower liver attenuation after adjustment for age, sex, and BMI (β = -11.10 HU, 95% CI: -16.40 to -5.79). Serum cortisol, cortisol after the 1-mg DST, aldosterone, and renin were not independently associated with hepatic steatosis, whereas UFC was independently associated with the L/S attenuation ratio in the hypercortisolism subgroup. CONCLUSIONS: Hepatic steatosis was similarly prevalent across PA, CS, and MACS, and was associated with metabolic factors, particularly DM, BMI, visceral adiposity, and hypertriglyceridemia. These findings support consideration of hepatic steatosis assessment in patients with functional adrenal disorders and metabolic risk factors.

Authors

Institutions

Publication Details

Journal
Endocrine Connections
Published
2026-11-13
DOI
https://doi.org/10.1530/ec-26-0493
Primary Topic
Liver Disease Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Hepatic Steatosis in Primary Aldosteronism, Cushing’s Syndrome, and Mild Autonomous cortisol secretion: Metabolic and Hormonal Associations

Matthias Philipp Fabritius, Markus Kroiss, Martín Reincke, Júnia Ribeiro de Oliveira Longo Schweizer et al.
5 links
Endocrine Connections
Liver Disease Diagnosis and Treatment
article

Hepatic Steatosis in Primary Aldosteronism, Cushing’s Syndrome, and Mild Autonomous cortisol secretion: Metabolic and Hormonal Associations

Matthias Philipp Fabritius, Markus Kroiss, Martín Reincke, Júnia Ribeiro de Oliveira Longo Schweizer, Christine Schmid‐Tannwald, Tuğçe Apaydın, Matthias Oettle, Friederike Völter, Moritz Schrenk, Nicole Reisch, Lalith Kumar, Isabel Stüfchen, Nabeel Mansour, Moritz Wildgruber, Max Seidensticker, Jens Ricke, Elisabeth Nowak
article en

Abstract

CONTEXT: Metabolic dysfunction-associated steatotic liver disease (MASLD) is closely linked to obesity, diabetes mellitus (DM), and dyslipidemia. Patients with primary aldosteronism (PA), Cushing's syndrome (CS) and mild autonomous cortisol secretion (MACS) exhibit metabolic abnormalities, but the relative contributions of hormonal and metabolic factors to hepatic steatosis remain unclear. OBJECTIVE: To evaluate MASLD prevalence and determinants in PA, CS, and MACS. DESIGN: Single-center retrospective cross-sectional study. METHODS: 243 treatment-naive patients underwent unenhanced abdominal computed tomography: 102 isolated PA, 60 CS, 47 MACS, and 34 PA with cortisol co-secretion. Hepatic steatosis was assessed using liver-to-spleen (L/S) attenuation ratio. Hepatic steatosis index (HSI), and triglyceride-glucose (TyG) index were calculated. RESULTS: MASLD prevalence was 28.4% in isolated PA, 26.6% in CS, 31.9% in MACS and 26.4% in PA with cortisol co-secretion. Liver attenuation and L/S ratio were similar across groups but correlated with visceral adiposity, glucose, HbA1c, triglycerides, HSI, and TyG index (all r>0.5, p<0.05). DM was independently associated with lower liver attenuation after adjustment for age, sex, and BMI (β = -11.10 HU, 95% CI: -16.40 to -5.79). Serum cortisol, cortisol after the 1-mg DST, aldosterone, and renin were not independently associated with hepatic steatosis, whereas UFC was independently associated with the L/S attenuation ratio in the hypercortisolism subgroup. CONCLUSIONS: Hepatic steatosis was similarly prevalent across PA, CS, and MACS, and was associated with metabolic factors, particularly DM, BMI, visceral adiposity, and hypertriglyceridemia. These findings support consideration of hepatic steatosis assessment in patients with functional adrenal disorders and metabolic risk factors.

Endocrine Connections
LMU Klinikum (DE), Acıbadem University (TR), Ludwig-Maximilians-Universität München (DE)
Deutsche Forschungsgemeinschaft
Good health and well-being
Liver Disease Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon